The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer

N Engl J Med. 2003 Jul 31;349(5):419-21. doi: 10.1056/NEJMp030061.
No abstract available

Publication types

  • Comment

MeSH terms

  • Adenocarcinoma, Clear Cell / drug therapy
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Carcinoma, Renal Cell / drug therapy*
  • Disease-Free Survival
  • Endothelial Growth Factors / antagonists & inhibitors*
  • Gene Silencing
  • Genes, Tumor Suppressor
  • Humans
  • Intercellular Signaling Peptides and Proteins
  • Kidney Neoplasms / drug therapy*
  • Ligases / genetics*
  • Lymphokines / antagonists & inhibitors*
  • Neovascularization, Pathologic / drug therapy*
  • Tumor Suppressor Proteins*
  • Ubiquitin-Protein Ligases*
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Von Hippel-Lindau Tumor Suppressor Protein

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Endothelial Growth Factors
  • Intercellular Signaling Peptides and Proteins
  • Lymphokines
  • Tumor Suppressor Proteins
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Bevacizumab
  • Ubiquitin-Protein Ligases
  • Von Hippel-Lindau Tumor Suppressor Protein
  • Ligases
  • VHL protein, human